1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
682C7695C387569C9852584170035F61F
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-patient-advocacy-2020-lessons-learned-top-pharma-companies-relationships-5564?OpenDocument
18
19OpenDocument
2018.206.48.142
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Patient Advocacy

Patient Advocacy 2020: Lessons Learned from Top Pharma Companies About Relationships with Patient Advocacy Groups

ID: 5564


Features:

24 Info Graphics

2 Data Graphics

25+ Metrics

18 Narratives


Pages/Slides: 33


Published: 2019


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Patient Advocacy 2020: Lessons Learned from Top Pharma Companies About Relationships with Patient Advocacy Groups”

STUDY OVERVIEW

As patient advocacy groups exert greater influence on key treatment and policy decisions, biopharmaceutical companies are intensifying their efforts to create and maintain relationships with these groups. At the same time, organizations need to be compliant with the regulatory policies and guidelines.

Best Practices, LLC undertook this benchmarking research to identify effective practices in patient advocacy group collaboration and relationship management. This study examines the key lessons learned by top pharma companies in partnering with patient advocacy to shape policies, improve access, and boost patient voice. The research includes a chapter with qualitative data from respondents regarding lessons learned and success stories.

KEY TOPICS

  • Understanding the “advocacy” landscape
  • Advocacy lessons learned
  • Success stories

SAMPLE KEY FINDINGS
  • Mapping the advocacy landscape to succeed: Assess the landscape of advocacy and community- interest groups to understand the broad spectrum of players, special interests and possible collaborators. Align objectives with different advocacy groups based on a particular therapeutic area or region. Be transparent while sharing information that can be deemed useful for advocacy groups. Aim for building long-term relationships.

METHODOLOGY

Best Practices, LLC engaged 74 leaders supporting patient advocacy at 61 biopharmaceutical companies through a benchmarking survey. More than 60% of participants are at the director/ senior director level. Nearly 65% of participants are from the United States.


Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Communications; Medical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Clinical Research; Research; Health Care; Laboratories


Companies Profiled:
AbbVie; Acceleron Pharma; Agendia; Alnylam Pharmaceuticals; Amicus Therapeutics; ApotheCom; Astellas; AveXis; AVROBIO; Baldwin Area Medical Center; Bayer; Biogen; BioMarin; Bionical Emas; Blue Earth Diagnostics; Bluebird Bio; Boehringer Ingelheim; Covance; CRISPR Therapeutics; Daiichi Sankyo; Dermira; Forum Pharmaceuticals; Grifols; GlaxoSmithKline ; Genzyme; Horizon Pharma; Incyte; Ipsen; Janssen; Johnson & Johnson; Lexicon Pharmaceuticals; Lundbeck; Mallinckrodt; Merck; Milestone Pharmaceuticals; MSD; Natera; NexGen Healthcare Communications; Novartis; Novo Nordisk; OTSUKA; Parkway Pantai; Pfizer; Pharmacyclics; Reata Pharmaceuticals; Retrophin; Sage Therapeutics; Sanofi; Servier; Shire; Spark Therapeutics; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; Theravance; Tillotts Pharma; UCB Pharma; Ultragenyx; Wave Life Sciences; Zimmer Biomet; Zogenix; The Mexican Organization for Rare Disorders (OMER)

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.